DPP4 and type 2 diabetes mellitus: PS matching was allowed for studies to assess the effects of GLP-1RA use in individuals with T2DM relative to those using other treatment modalities, including various anti-diabetes drugs, such as insulin or metformin, DPP4 inhibitors, or long-acting insulins (LAI) [20,21,23,24].